Innate Pharma SAIPHA
What Innate Pharma SA does.
Innate Pharma S.A. is a clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need.
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $69.8M | $24.7M | $57.7M | $61.6M | $20.1M | $9.0M |
| Net income | -$64.0M | -$52.8M | -$58.1M | -$7.6M | -$49.5M | -$49.2M |
| Free cash flow | -$52.7M | -$59.4M | -$19.7M | -$32.9M | -$7.3M | -$52.9M |
More on IPHA.
- Innate Pharma SA summary
- Innate Pharma SA financial statements
- Innate Pharma SA key metrics
- Innate Pharma SA health scores and style box
- Innate Pharma SA earnings
- Innate Pharma SA dividends
- Innate Pharma SA valuation
- Innate Pharma SA ownership and insiders
- Innate Pharma SA peers
Figures from Innate Pharma SA's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.